Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio

Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio

The following was taken from PR Newswire and you can read it here: https://www.prnewswire.com/news-releases/research-bridge-partners-seed-capital-investment-in-asalyxa-bio-advances-dr-lola-eniola-adefesos-immune-cell-targeted-therapeutic-platform-301242853.html

“Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities

AUSTIN, Texas, March 9, 2021 /PRNewswire/ — Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities with the commercialization resources of Silicon Valley— announced a seed capital investment in Asalyxa Bio, a University of Michigan spinout that has developed a drug-delivery technology to treat a wide range of inflammatory diseases. The company also announced the designation of Dr. Lola Eniola-Adefeso, Asalyxa Bio’s Chief Scientific Officer, as Research Bridge Partners Fellow. Research Bridge Partners’ program-related investment will help the company fund development of core technologies and intellectual property, while supporting IND-enabling studies required to obtain the permission of regulatory authorities to begin human clinical testing. With this investment, James Graham, Research Bridge Partners Managing Director of Investments, has joined the company’s board of directors. Asalyxa Bio’s lead program, ASX-100, delivers an anti-inflammatory agent directly to overreactive neutrophils—a long-ignored white blood cell that may be implicated in the immune system overreaction known as a “cytokine storm.”

Next